Olysio® (simeprevir)

When is Olysio® contraindicated?

UPDATE: Janssen Therapeutics discontinued Olysio effective May 25, 2018.

There are no specific contraindications to Olysio®. However, the same contraindications that pertain to other medications taken in combination with Olysio® will also apply to Olysio® combination treatment.

For those taking Olysio® in combination with sofosbuvir, you should be aware of the contraindications specific to sofosbuvir which can be viewed here.

For those taking Olysio® in combination with ribavirin, this treatment is contraindicated in pregnant women or those that may become pregnant as well as men whose female partner is pregnant, due to the risks for birth defects and fetal death associated with ribavirin.

For more specific information, refer to the prescribing information for peginterferon alfa and ribavirin for a list of all contraindications.

Last Updated: May 2018

What is the dosage for Olysio®? What types of adverse reactions were reported when taking Olysio®?

References

A New Chronic Hepatitis C Treatment - Olysio (simeprevir). http://www.olysio.com/, Janssen Therapeutics. Retrieved May 8, 2015.

FDA Approved New Treatment for Hepatitis C Cure. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm, U.S. Food and Drug Administration. Retrieved May 8, 2015.

Helpful Tips When Facing Chronic Hepatitis C. http://www.olysio.com/sites/default/files/pdf/fact-sheets.pdf, Janssen Therapeutics. Retrieved May 8, 2015.

Highlights of Prescribing Information - OLYSIO. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf, Janssen Therapeutics. Retrieved May 8, 2015.